Fig. 5From: Characterization of a splice-site mutation in the tumor suppressor gene FLCN associated with renal cancerTo analyse the impact of the patient mutation on the protein level, HEK293T cells expressing FLCN WT or Mut fused to GFP using the TALEN technology were generated. a and b Western blot analyses reveals that the mutant protein is hardly expressed. This could in part be alleviated with MG-132 (a, treatment with 10 μM for 2 h) or chloroquine (b, treatment with 50 μM for 24 h), indicating an involvement of the proteasome and lysosome in the degradation process. Tubulin served as loading control (p =3, error bars indicate SEM, * = p < 0.05, n.s. = not significant, two tailed t-test)Back to article page